May 4, 2020 / 11:46 AM / a month ago

Vir, Alnylam pick coronavirus therapy candidate, plan human trials by year end

May 4 (Reuters) - Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc have identified a drug candidate for treating COVID-19 and plan to begin human testing by the end of the year, the companies said on Monday.

The therapy candidate makes use of gene-silencing RNA interference (RNAi) technology that targets and “silences” specific genetic material, blocking the production of deadly proteins that cause diseases. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below